Latigo Biotherapeutics launches with $135M Series A funding to advance development of non-opioid pain treatments

Thousands Oaks, CA, February 14, 2024 (PRNewswire) -- Latigo Biotherapeutics has announced that it has completed a $135 million series A financing round.  The company was incubated by Westlake Village BioPartners which also spearheaded the series A funding alongside co-leads 5AM Ventures and Foresite Capital, with additional participation from Corner Ventures.  Inc.   Latigo is focused on non-opioid pain treatments targeting pain at its root.

Read full article here.